Abstract

Most affinity-maturation campaigns for antibodies and T-cell receptors (TCRs) operate on the residues at the binding site, located within the loops known as complementarity-determining regions (CDRs). Accordingly, mutations in contact residues, or so-called "second shell" residues, that increase affinity are typically identified by directed evolution involving combinatorial libraries. To determine the impact of residues located at a distance from the binding site, here we used single-codon libraries of both CDR and non-CDR residues to generate a deep mutational scan of a human TCR against the cancer antigen MART-1·HLA-A2. Non-CDR residues included those at the interface of the TCR variable domains (Vα and Vβ) and surface-exposed framework residues. Mutational analyses showed that both Vα/Vβ interface and CDR residues were important in maintaining binding to MART-1·HLA-A2, probably due to either structural requirements for proper Vα/Vβ association or direct contact with the ligand. More surprisingly, many Vα/Vβ interface substitutions yielded improved binding to MART-1·HLA-A2. To further explore this finding, we constructed interface libraries and selected them for improved stability or affinity. Among the variants identified, one conservative substitution (F45βY) was most prevalent. Further analysis of F45βY showed that it enhanced thermostability and increased affinity by 60-fold. Thus, introducing a single hydroxyl group at the Vα/Vβ interface, at a significant distance from the TCR·peptide·MHC-binding site, remarkably affected ligand binding. The variant retained a high degree of specificity for MART-1·HLA-A2, indicating that our approach provides a general strategy for engineering improvements in either soluble or cell-based TCRs for therapeutic purposes.

Highlights

  • Most affinity-maturation campaigns for antibodies and T-cell receptors (TCRs) operate on the residues at the binding site, located within the loops known as complementarity-determining regions (CDRs)

  • Chain of TCR; V␤, variable region of ␤ chain of TCR; CDR, complementaritydetermining region; FR, framework region; single-chain TCR (scTCR), single chain T-cell receptor; pep1⁄7MHC, peptide complexed with major histocompatibility complex; HLA, human leukocyte antigen; KD, dissociation constant; Tm, melting temperature; DSF, differential scanning fluorimetry; SPR, surface plasmon resonance; erodimers that recognize their antigens through the action of six hypervariable loops called complementarity-determining regions (CDRs)

  • A TCR isolated from the human T-cell clone called INR1-T1, specific for MART-11⁄7HLA-A2, was engineered previously as a single-chain TCR (V␤16-linker-V␣2; TRBV30-linkerTRAV12-2 in IMGT nomenclature) by identifying mutations that enabled yeast surface display and expression as a soluble protein [23]

Read more

Summary

Edited by Peter Cresswell

Most affinity-maturation campaigns for antibodies and T-cell receptors (TCRs) operate on the residues at the binding site, located within the loops known as complementarity-determining regions (CDRs). The combination of CDR mutations that individually yielded modest improvements in binding allowed the identification of TCR mutants that were 100-fold higher affinity, on par with directed evolution strategies [41] Using both deep mutational scans and directed evolution, here we examined another human TCR against MART-11⁄7HLAA2, called T1, with a goal of determining whether V region interfaces could be engineered for greater stability and expression properties. Numerous mutants were identified from the sequence fitness landscape where a substitution at the V␣/V␤ interface yielded enrichment, similar to the number found in CDRs, a finding that could be due to higher yeast surface levels (e.g. due to improved stability) or higher affinity Based on these results and the known structures of TCRs, we generated dual-codon libraries of opposing pairs of interface residues and subjected these and the single-codon libraries to antigen selection by high-speed flow sorting. They suggest that V␣/V␤ interface substitutions should be included in efforts to identify TCRs with affinity and stability improvements for use as soluble therapeutics or in adoptive T-cell therapies

Results
Discussion
Experimental procedures
Protein modeling by RosettaBackrub
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call